Efficacy and Safety of Transcatheter Mitral Valve Edge-to-Edge Repair with a MitraClip Device in Real-World Canadian Practice

Résumé fourni par la source

BACKGROUND Mitral transcatheter edge-to-edge repair (M-TEER) is a treatment option for patients with symptomatic mitral regurgitation (MR). The real-world experience with M-TEER in Canada has not been previously reported. METHODS We conducted an observational study of 1,191 patients from 11 Canadian centers undergoing M-TEER with MitraClip. M-TEER databases from each center were centrally collected and merged into a single Canada-wide database. The primary outcome was MR severity before M-TEER versus up to 1-year after M-TEER. Secondary outcomes included hospitalizations for heart failure (HHF) and NYHA functional class. RESULTS MR etiology was degenerative in 41% and functional in 59%. The mean age was 76 years and 36% were women. The proportion with MR ≥ 3+ was 97.3% before versus 11.0% up to 1-year after M-TEER (absolute risk difference [ARD] 86.4%, P<0.001). HHF occurred in 50.7% before versus 10.3% up to 1-year after M-TEER (ARD 40.4%, P<0.001), with similar benefit in patients with functional (ARD 44.8%, 95% CI 39.5-50.1) and degenerative (ARD 34.8%, 95% CI 29.0-40.6) MR. NYHA class III-IV HF was present in 82.8% before versus 16.6% up to 1-year after M-TEER (ARD 66.2%, P<0.001). Single-leaflet detachment (1.0%) MV surgery (2.2%) were infrequent. Mortality was 1.3% in-hospital and 12.7% at 1-year. CONCLUSION In this first national registry of M-TEER in Canada, M-TEER resulted in a sustained reduction in MR and was associated with reduced heart failure hospitalizations and improvement in NYHA functional class, with a high degree of safety. This benefit was consistent in patients with functional and degenerative MR.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.